Posted by Cloudbreak Therapeutics, LLC has sponsored a multicenter, randomized, double-masked, vehicle-controlled, parallel group study using CBT-008 (buffered solution of methyl BCD) for the treatment of Meibomian gland dysfunction (MGD). The level of MeBCD is 0, 2.5 and 10%. Duration: 1 month.
The meibomian glands, named after the German doctor who studied them, make an oil called meibum. Meibum, water, and mucus form the three layers of tear film, the fluid that keeps the eyes moist. The oil helps prevent the water layer on the eye surface from evaporating or drying out too quickly. Changes to the amount or quality of the oil, or to the glands themselves, can lead to MGD. It’s often the result of a combination of things. The most common type, obstructive MGD, happens when the gland openings get clogged, and less and less oil reaches the eye surface.
Cloudbreak Pharmaceutical is a clinical-stage biotechnology company focusing on ocular drug development. Founded in September 2015 in Irvine, California, USA, Cloudbreak Pharmaceutical quickly advanced our first drug candidate through lead selection, pre-clinical IND-enabling studies and successful IND submission.
NCT05261386: Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction. https://clinicaltrials.gov/ct2/show/NCT05261386